CDK1 and acute myeloid leukemia: As a more direct support of the oncogenic role of ARPP19 in AML, transient ARPP19 knockdown by siRNA decreased expression of a well-validated PP2A target [19], and oncoprotein, MYC, and of cell cycle mediator CDK1 in both cell lines (Figure 3a,b).